Back

Novel PCSK9 outcomes in perspective: lessons from FOURIER & ODYSSEY.

25 August 2018 (15:50 - 16:10)
Organised by:
Congress Presentation Part of: PCSK9 inhibition: science, outcomes and guidance (EBAC Accredited) Lipids ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Jennifer Robinson

University of Iowa, Iowa (United States of America)

4 More presentations in this session

Presentation thumbnail
Introduction - PCSK9 inhibition: science, outcomes and guidance.
Professor P. Barter (Sydney, AU) Professor J. Kastelein (Amsterdam, NL)
Presentation thumbnail
PCSK9 as target for treatment: the genetic validation.
Professor B. Ference (Cambridge, GB)
Presentation thumbnail
Targeting PCSK9 in clinical practice: guidance and future.
Professor J. Kastelein (Amsterdam, NL)
Presentation thumbnail
Discussion and summary - PCSK9 inhibition: science, outcomes and guidance
Professor P. Barter (Sydney, AU)

Access the full session

Session thumbnail
PCSK9 inhibition: science, outcomes and guidance (EBAC Accredited)

The Event

Event poster

ESC Congress 2018

25 August 2018 15:50 CET
You may be interested in
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021
thumbnail
Congress Presentation
Discussant review - AMUNDSEN
29 August 2026
thumbnail
Congress Presentation
A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
30 August 2025
thumbnail
Congress Presentation
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources